These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37989928)

  • 21. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
    Bose P; Verstovsek S
    Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Momelotinib for the treatment of myelofibrosis.
    Bose P
    Blood; 2024 Aug; 144(7):708-713. PubMed ID: 38958484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
    Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
    Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
    Santos FP; Kantarjian HM; Jain N; Manshouri T; Thomas DA; Garcia-Manero G; Kennedy D; Estrov Z; Cortes J; Verstovsek S
    Blood; 2010 Feb; 115(6):1131-6. PubMed ID: 20008298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.
    Pardanani A; Gotlib J; Roberts AW; Wadleigh M; Sirhan S; Kawashima J; Maltzman JA; Shao L; Gupta V; Tefferi A
    Leukemia; 2018 Apr; 32(4):1035-1038. PubMed ID: 29263442
    [No Abstract]   [Full Text] [Related]  

  • 26. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
    Verstovsek S
    Postgrad Med; 2013 Jan; 125(1):128-35. PubMed ID: 23391678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
    Verstovsek S; Gerds AT; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC; Egyed M; Fox ML; McLornan D; Perkins A; Yoon SS; Gupta V; Kiladjian JJ; Granacher N; Lee SE; Ocroteala L; Passamonti F; Harrison CN; Klencke BJ; Ro S; Donahue R; Kawashima J; Mesa R;
    Lancet; 2023 Jan; 401(10373):269-280. PubMed ID: 36709073
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety.
    Verstovsek S; Mesa RA; Livingston RA; Hu W; Mascarenhas J
    J Hematol Oncol; 2023 Jul; 16(1):82. PubMed ID: 37501130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis.
    Abdelrahman RA; Begna KH; Al-Kali A; Hogan WJ; Litzow MR; Pardanani A; Tefferi A
    Br J Haematol; 2015 Apr; 169(1):77-80. PubMed ID: 25511866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fedratinib: First Approval.
    Blair HA
    Drugs; 2019 Oct; 79(15):1719-1725. PubMed ID: 31571162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices.
    Tefferi A; Pardanani A; Gangat N
    Am J Hematol; 2024 Feb; 99(2):300-308. PubMed ID: 38164985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
    Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
    Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera.
    Bai J; Ai L; Zhang L; Yang FC; Zhou Y; Xue Y
    Am J Hematol; 2015 Dec; 90(12):1116-21. PubMed ID: 26370613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
    Griesshammer M; Sadjadian P
    Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.
    Ogasawara K; Zhou S; Krishna G; Palmisano M; Li Y
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):891-898. PubMed ID: 31444617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.
    Mesa R; Harrison C; Oh ST; Gerds AT; Gupta V; Catalano J; Cervantes F; Devos T; Hus M; Kiladjian JJ; Lech-Maranda E; McLornan D; Vannucchi AM; Platzbecker U; Huang M; Strouse B; Klencke B; Verstovsek S
    Leukemia; 2022 Sep; 36(9):2261-2268. PubMed ID: 35869266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis.
    DeAngelo DJ; Mesa RA; Fiskus W; Tefferi A; Paley C; Wadleigh M; Ritchie EK; Snyder DS; Begna K; Ganguly S; Ondovik MS; Rine J; Bhalla KN
    Br J Haematol; 2013 Aug; 162(3):326-35. PubMed ID: 23701016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 1 study of the Janus kinase 2 (JAK2)
    Verstovsek S; Mesa RA; Salama ME; Li L; Pitou C; Nunes FP; Price GL; Giles JL; D'Souza DN; Walgren RA; Prchal JT
    Leuk Res; 2017 Oct; 61():89-95. PubMed ID: 28934680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
    Shide K; Takenaka K; Kitanaka A; Numata A; Kameda T; Yamauchi T; Inagaki A; Mizuno S; Takami A; Ito S; Hagihara M; Usuki K; Maekawa T; Sunami K; Ueda Y; Tsutsui M; Ando M; Komatsu N; Ozawa K; Kurokawa M; Arai S; Mitani K; Akashi K; Shimoda K
    Ann Hematol; 2024 Jan; 103(1):97-103. PubMed ID: 37946031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
    Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
    PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.